Abstract
Hormonal therapy has been used erratically to treat epithelial ovarian cancer since the mid 1960s; however, there has been little progress until recently in our understanding of which patients might benefit from treatment. Some clarity in the field is now beginning to emerge from recent studies, which have started to define biomarkers within epithelial ovarian cancers that link with hormonal response and thereby indicate which cohort of patients might be amenable to hormonal treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 548-53 |
| Number of pages | 6 |
| Journal | Current opinion in oncology |
| Volume | 20 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2008 |